MA26870A1 - Derives heterocycliques benzocondenses de nicotinamide utiles comme inhibiteurs selectifs des isozymes pde4 - Google Patents

Derives heterocycliques benzocondenses de nicotinamide utiles comme inhibiteurs selectifs des isozymes pde4

Info

Publication number
MA26870A1
MA26870A1 MA26739A MA26739A MA26870A1 MA 26870 A1 MA26870 A1 MA 26870A1 MA 26739 A MA26739 A MA 26739A MA 26739 A MA26739 A MA 26739A MA 26870 A1 MA26870 A1 MA 26870A1
Authority
MA
Morocco
Prior art keywords
useful
nicotinamide
selective inhibitors
heterocyclic derivatives
pde4
Prior art date
Application number
MA26739A
Other languages
English (en)
Inventor
James Chamber Robert
Marfat Anthony
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of MA26870A1 publication Critical patent/MA26870A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Ophthalmology & Optometry (AREA)

Abstract

DEPOSANT Société dite: PFIZERPRODUCTS INC. REVENDICATION DE PRIORITES US 31 Janvier2000 60/179,284 Voir en annexe le titre de l'invention et le texte de l'abrégé Dérivés heterocycliques benzocondenses de nicotinamide, utiles comme inhibiteurs sélectifs des isozymes PDE4 Composés utiles comme inhibiteurs de PDE4 dans le traitement de maladies régulées par l'activation et la dégranulation des cellules éosinophiles, notamment de l'asthme, de la bronchite chronique et d'une maladie pulmonaire obstructrice chronique, répondant à la formule (1.0.0.) dans ladite formule, R5 et R6 sont pris conjointement pour former un groupement de formules partielles (1.1.1.) à (1.1.5) ou un de leurs sels pharmaceutiquement acceptables.
MA26739A 2000-01-31 2002-07-23 Derives heterocycliques benzocondenses de nicotinamide utiles comme inhibiteurs selectifs des isozymes pde4 MA26870A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US17928400P 2000-01-31 2000-01-31

Publications (1)

Publication Number Publication Date
MA26870A1 true MA26870A1 (fr) 2004-12-20

Family

ID=22655931

Family Applications (1)

Application Number Title Priority Date Filing Date
MA26739A MA26870A1 (fr) 2000-01-31 2002-07-23 Derives heterocycliques benzocondenses de nicotinamide utiles comme inhibiteurs selectifs des isozymes pde4

Country Status (40)

Country Link
US (1) US7354941B2 (fr)
EP (1) EP1252158B1 (fr)
JP (1) JP3917863B2 (fr)
KR (1) KR20020072299A (fr)
CN (1) CN1404481A (fr)
AP (1) AP2002002589A0 (fr)
AR (1) AR027337A1 (fr)
AT (1) ATE293624T1 (fr)
AU (1) AU2700201A (fr)
BG (1) BG106852A (fr)
BR (1) BR0107964A (fr)
CA (1) CA2398182C (fr)
CO (1) CO5261634A1 (fr)
CZ (1) CZ20022410A3 (fr)
DE (1) DE60110205T2 (fr)
EA (1) EA004885B1 (fr)
EE (1) EE200200425A (fr)
ES (1) ES2238415T3 (fr)
GE (1) GEP20043302B (fr)
GT (1) GT200100022A (fr)
HN (1) HN2001000019A (fr)
HU (1) HUP0204262A2 (fr)
IL (1) IL150641A0 (fr)
IS (1) IS6421A (fr)
MA (1) MA26870A1 (fr)
MX (1) MXPA02007419A (fr)
NO (1) NO20023613L (fr)
NZ (1) NZ519547A (fr)
OA (1) OA12169A (fr)
PA (1) PA8511201A1 (fr)
PE (1) PE20011058A1 (fr)
PL (1) PL357995A1 (fr)
PT (1) PT1252158E (fr)
SK (1) SK10142002A3 (fr)
SV (1) SV2002000299A (fr)
TN (1) TNSN01020A1 (fr)
TR (1) TR200201880T2 (fr)
UY (1) UY26569A1 (fr)
WO (1) WO2001057036A1 (fr)
ZA (1) ZA200206033B (fr)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE457169T1 (de) * 1998-10-15 2010-02-15 Imp Innovations Ltd Verbindungen für die behandlung von gewichtsverlust
AU3467001A (en) * 2000-01-28 2001-08-07 Alza Corp Liposomes containing an entrapped compound in supersaturated solution
JP2004518629A (ja) 2000-09-18 2004-06-24 イー・アイ・デュポン・ドウ・ヌムール・アンド・カンパニー 殺菌・殺カビ剤として使用するためのピリジニルアミド類およびイミド類
KR20030070150A (ko) 2001-01-31 2003-08-27 화이자 프로덕츠 인크. Ｐｄｅ4 이소자임 억제제로서 유용한 에테르 유도체
US7250518B2 (en) 2001-01-31 2007-07-31 Pfizer Inc. Nicotinamide acids, amides, and their mimetics active as inhibitors of PDE4 isozymes
EE200300360A (et) 2001-01-31 2003-12-15 Pfizer Products Inc. PDE4 isosüümide inhibiitoritena kasutatavad nikotiinamiidi biarüülderivaadid
EP1355907A1 (fr) 2001-01-31 2003-10-29 Pfizer Products Inc. Derives amide acide de thiazolyle, oxazolyle, pyrrolyle et imidazolyle utilises en tant qu'inhibiteurs des isozymes pde4
GB0118373D0 (en) * 2001-07-27 2001-09-19 Glaxo Group Ltd Novel therapeutic method
PL210463B1 (pl) * 2001-09-19 2012-01-31 Nycomed Gmbh Zastosowanie kombinacji roflumilastu z diklofenakiem w leczeniu zapalnych chorób stawów
HUP0500078A3 (en) * 2001-09-19 2010-07-28 Nycomed Gmbh Pharmaceutical composition containing a combination of a pde inhibitor and a leukotriene receptor antagonist
IS7221A (is) * 2001-11-15 2004-04-15 Memory Pharmaceuticals Corporation Hringlaga adenosínmónófosfat fosfódíesterasa 4D7 ísóform og aðferðir til notkunar þeirra
US6756392B2 (en) 2002-02-11 2004-06-29 Pfizer Inc Nicotinamide derivatives useful as PDE4 inhibitors
RS70104A (en) 2002-02-11 2007-02-05 Pfizer Limited, Nicotinamide derivatives useful as pde4 inhibitors
US6962940B2 (en) 2002-03-20 2005-11-08 Celgene Corporation (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
PL375631A1 (en) * 2002-11-27 2005-12-12 Altana Pharma Ag Pde4 and pde3/4 inhibitors for use in the treatment of cachexia
AU2003300076C1 (en) 2002-12-30 2010-03-04 Angiotech International Ag Drug delivery from rapid gelling polymer composition
CA2520577A1 (fr) * 2003-03-31 2004-10-14 Kyowa Hakko Kogyo Co., Ltd. Composition pharmaceutique
WO2004087150A1 (fr) * 2003-03-31 2004-10-14 Kyowa Hakko Kogyo Co. Ltd. Composition pour medicaments
JPWO2004087151A1 (ja) * 2003-03-31 2006-06-29 協和醗酵工業株式会社 医薬組成物
CN100372944C (zh) * 2003-04-10 2008-03-05 弗·哈夫曼-拉罗切有限公司 Pde4d在筛选治疗动脉粥样硬化的药物中的用途
WO2004104022A2 (fr) * 2003-05-16 2004-12-02 The General Hospital Corporation Compositions contenant un facteur chimio-tactique epithelial pathogene (eicosanoide et hepoxiline a3), leurs inhibiteurs et leurs procedes d'utilisation
GB0317498D0 (en) * 2003-07-25 2003-08-27 Pfizer Ltd Compounds
GB0317484D0 (en) 2003-07-25 2003-08-27 Pfizer Ltd Nicotinamide derivatives useful as pde4 inhibitors
US7132435B2 (en) 2003-07-25 2006-11-07 Pfizer Inc. Compounds
GB0317471D0 (en) * 2003-07-25 2003-08-27 Pfizer Ltd Novel compounds
US7153870B2 (en) 2003-07-25 2006-12-26 Pfizer Inc. Nicotinamide derivatives useful as PDE4 inhibitors
GB0317516D0 (en) 2003-07-25 2003-08-27 Pfizer Ltd Nicotinamide derivatives useful as PDE4 inhibitors
AR049384A1 (es) 2004-05-24 2006-07-26 Glaxo Group Ltd Derivados de purina
CA2594785A1 (fr) * 2005-01-21 2006-07-27 Pfizer Limited Formes cristallines cis-5-fluoro-n-[4-(2-hydroxy-4-methylbenzamido) cyclohexyl]-2-(tetrahydrothiopyran-a-yloxy) nicotinamide
EP1683795A1 (fr) * 2005-01-21 2006-07-26 Pfizer Limited Formes crystallines de cis-5-fluoro-N-¬4-(2-hydroxy-4-methylbenzamido)cyclohexyl|-2-(tetrahydrothiopyran-4-yloxy)nicotinamide
GB0514809D0 (en) 2005-07-19 2005-08-24 Glaxo Group Ltd Compounds
GB0624282D0 (en) * 2006-12-05 2007-01-10 Cavalla David Treatment of cachexia
WO2008079328A2 (fr) * 2006-12-22 2008-07-03 Creighton University Acides gras oméga-5 utiles dans l'inhibition de la 5-lipoxygénase et dans le traitement du cancer
CA2682730A1 (fr) * 2007-04-11 2008-10-23 Alcon Research, Ltd. Utilisation d'un inhibiteur de tnf.alpha. et d'une anti-histamine pour traiter la rhinite allergique et la conjonctivite allergique
EP2196465A1 (fr) 2008-12-15 2010-06-16 Almirall, S.A. Dérivés de (3-oxo)pyridazin-4-ylurée comme inhibiteurs de PDE4
EP2226323A1 (fr) 2009-02-27 2010-09-08 Almirall, S.A. Nouveaux dérivés de tétrahydropyrazolo [3,4-c]isoquinoléine-5-amine
USRE46608E1 (en) 2009-09-01 2017-11-14 Catabasis Pharmaceuticals, Inc. Fatty acid niacin conjugates and their uses
MX2012002710A (es) 2009-09-01 2012-04-19 Catabasis Pharmaceuticals Inc Conjugados de niacina y acidos grasos y sus usos.
EP2380890A1 (fr) 2010-04-23 2011-10-26 Almirall, S.A. Nouveaux dérivés de 7,8-dihydro-1,6-naphthyridin-5(6h)-one comme PDE4 inhibiteurs
EP2386555A1 (fr) * 2010-05-13 2011-11-16 Almirall, S.A. Nouveaux dérivés de cyclohéxylamine dotés d'activités agoniste bêta 2 adrénergique et antagoniste muscarinique m3
EP2394998A1 (fr) 2010-05-31 2011-12-14 Almirall, S.A. Dérivés de 3-(5-Amino-6-oxo-1,6-dihydropyridazin-3-yl)-biphenyl en tant qu'inhibiteurs de la PDE4
WO2016146079A1 (fr) * 2015-03-17 2016-09-22 Sheau-Long Lee Utilisation de ginsenoside m1 pour la prévention ou le traitement de la silicose
US11116737B1 (en) 2020-04-10 2021-09-14 University Of Georgia Research Foundation, Inc. Methods of using probenecid for treatment of coronavirus infections

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4861891A (en) * 1988-08-31 1989-08-29 Pfizer Inc. Antidepressant N-substituted nicotinamide compounds
TW429148B (en) * 1995-10-27 2001-04-11 Pfizer Pharmaceutical agents for the treatment of acute and chronic inflammatory diseases
PL336148A1 (en) 1997-04-04 2000-06-05 Pfizer Prod Inc Nicotinamide derivatives

Also Published As

Publication number Publication date
EP1252158A1 (fr) 2002-10-30
OA12169A (en) 2006-05-08
JP3917863B2 (ja) 2007-05-23
AR027337A1 (es) 2003-03-26
EA200200662A1 (ru) 2002-12-26
NO20023613L (no) 2002-09-30
SK10142002A3 (sk) 2003-11-04
AU2700201A (en) 2001-08-14
TR200201880T2 (tr) 2002-11-21
CN1404481A (zh) 2003-03-19
NZ519547A (en) 2004-03-26
EA004885B1 (ru) 2004-08-26
ES2238415T3 (es) 2005-09-01
IL150641A0 (en) 2003-02-12
GEP20043302B (en) 2004-02-10
CA2398182A1 (fr) 2001-08-09
JP2003522176A (ja) 2003-07-22
CZ20022410A3 (cs) 2003-08-13
UY26569A1 (es) 2001-08-27
SV2002000299A (es) 2002-07-03
EP1252158B1 (fr) 2005-04-20
DE60110205D1 (de) 2005-05-25
ATE293624T1 (de) 2005-05-15
BG106852A (bg) 2003-02-28
HN2001000019A (es) 2001-09-06
BR0107964A (pt) 2002-10-29
PL357995A1 (en) 2004-08-09
US7354941B2 (en) 2008-04-08
AP2002002589A0 (en) 2002-09-30
PE20011058A1 (es) 2001-10-23
KR20020072299A (ko) 2002-09-14
CA2398182C (fr) 2007-03-13
TNSN01020A1 (fr) 2005-11-10
MXPA02007419A (es) 2002-12-09
NO20023613D0 (no) 2002-07-30
PA8511201A1 (es) 2002-12-11
EE200200425A (et) 2003-10-15
GT200100022A (es) 2001-10-19
US20030186989A1 (en) 2003-10-02
DE60110205T2 (de) 2006-01-26
HUP0204262A2 (hu) 2003-04-28
PT1252158E (pt) 2005-09-30
ZA200206033B (en) 2003-07-29
IS6421A (is) 2002-06-13
WO2001057036A1 (fr) 2001-08-09
CO5261634A1 (es) 2003-03-31

Similar Documents

Publication Publication Date Title
MA26870A1 (fr) Derives heterocycliques benzocondenses de nicotinamide utiles comme inhibiteurs selectifs des isozymes pde4
MA27174A1 (fr) Derives de nicotinamide utiles comme inhibiteurs de pde4.
TW200604174A (en) Substituted pyridones as inhibitors of poly(adp-ribose) polymerase (parp)
MA26873A1 (fr) Derives de purine
MA26983A1 (fr) Derives biaryliques de nicotinamide utiles comme inhibiteurs d'iso-enzymes pde4
MA27009A1 (fr) Derives de pyrazole pour le traitement d'une infection par le vih
MXPA05010958A (es) Derivados indazol como inhibidores jnk.
MA27436A1 (fr) Derives de pyridine inhibiteurs de la cox-2
ATE437872T1 (de) Proteinkinaseinhibitoren
NO20050851L (no) Kaspase-inhibitorer og anvendelser derav
MA28747B1 (fr) Dérivés de pyridine
MA26875A1 (fr) Composes azapolycycliques a noyau aryle condensé
EP1248612A4 (fr) Nouveaux composes et compositions utilises comme inhibiteurs de protease
DE60316013D1 (de) Heteroaryl-pyrimidinderivate als jak-inhibitoren
AU4437896A (en) Piperidine derivatives having tachykinin antagonist activity
DK0672031T3 (da) Catecholdiethere som selektive PDE IV-inhibitorer
HUP0401047A2 (hu) Triazolo[4,5-d]pirimidin-származékok, alkalmazásuk purinergikus receptor-antagonistákként és a vegyületet tartalmazó gyógyszerkészítmények
MA26985A1 (fr) Derives d'amides de thiazolyl-,oxazolyl-pyrrolyl-et imidazolyl-acides utiles comme inhibiteurs d'isozymes pde4
TR200201505T2 (tr) Terapötik maddeler olarak pirazolopirimidinler
YU69902A (sh) Novi derivati piperazina
MA27146A1 (fr) INHIBITEURS DU FACTEUR Xa ET D'AUTRES SERINE-PROTEASES IMPLIQUEES DANS LA CASCADE DE LA COAGULATION.
MA27716A1 (fr) 4-aminopyrimidine-5-one
PT828728E (pt) Di-hidrobenzofuranos de fenilo
MA26701A1 (fr) PYRAZOLOPYRIMIDINONES NOUVELLES INHIBITRICES DE PDE-5 GMPc, PROCEDE POUR LEUR PREPARATION ET COMPOSTIONS PHARMACEUTIQUES LES CONTENANT.
ATE230404T1 (de) Cyclohexyldihydrobenzofurane